Strategic M&A Aker BioMarine is engaging in mergers and exploring strategic alternatives for its Human Health Ingredients business, signaling ongoing corporate reshaping and potential opportunities for partnerships, licensing, or acquisition discussions that could open cross-sell or co-development avenues.

Revenue Growth Q2 2026 revenues rose to $57.9M, driven by the Human Health Ingredients segment, and Q2 2026 krill oil sales also showed solid volume growth with a 21 percent increase, indicating robust demand and potential upsell of premium krill oil and related nutraceutical products.

Sustainability Edge Long-term focus on sustainable sourcing and energy stewardship is demonstrated by a 24/7 renewable energy agreement with ENGIE, offering a compelling angle for sales to institutions and brands prioritizing ESG credentials in ingredient sourcing and supply chain partnerships.

Financial Scale Revenue range of $100M-$250M and a sizable employee base positions Aker BioMarine as a credible partner for larger co-development or contract manufacturing deals, with potential to cross-sell plant-based and algae-derived innovations from spin-offs like FloraMarine.

Innovation Ecosystem Active portfolio of brands and spin-offs (Superba Krill Oil, Lysoveta, Understory, FloraMarine, AION) provides multiple entry points for collaboration, licensing, or distribution agreements across pharmaceutical, nutraceutical, and sustainability-focused segments.